The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems.
In the previous paper (Gerfen et al., 1987) mesostriatal dopaminergic neurons were shown to be subdivided into dorsal and ventral tiers that project to the striatal matrix and patch compartments, respectively. The present study provides experimental evidence that these patch-matrix mesostriatal dopaminergic systems are biochemically and developmentally distinct. A 28 kDa calcium-binding protein (CaBP, or calbindin-D28 kDa) is expressed in dorsal tier mesostriatal dopaminergic neurons. The distribution of such neurons, located in the ventral tegmental area, dorsal tier of the substantia nigra pars compacta, and retrorubral area, matches that of dopaminergic neurons that project to the striatal matrix. Dopaminergic neurons that do not express CaBP--those in the ventral tier of the pars compacta and in the pars reticulata--are distributed in a pattern that matches the origin of the dopaminergic projection to the striatal patches. During development, dopaminergic afferents to the striatal patch compartment are in place prior to the development of those to the matrix. Injections of the neurotoxin 6-hydroxydopamine (6-OHDA) into the striatum of newborn rats result in a selective and long-lasting depletion of dopaminergic afferents in the striatal patches. The later-developing matrix projection is relatively spared by such lesions. The distribution of surviving dopaminergic neurons, labeled with tyrosine hydroxylase (TH) immunoreactivity, matches the pattern of dorsal tier neurons previously shown to provide inputs to the matrix. Surviving neurons also express CaBP immunoreactivity and have dendrites that spread mediolaterally, in the plane of the pars compacta. On the other hand, those neurons that project to the patches are selectively lesioned by the neonatal 6-OHDA striatal injections, do not express CaBP, and have dendrites that are directed ventrally into the pars reticulata.
D000818:Animals; D001927:Brain Diseases / Q000503:physiopathology; D064026:Calbindins; D003342:Corpus Striatum / Q000166:cytology*; D004298:Dopamine / Q000032:analysis*; D006892:Hydroxydopamines; D008636:Mesencephalon / Q000032:analysis* / Q000166:cytology; D009434:Neural Pathways / Q000032:analysis / Q000166:cytology; D016627:Oxidopamine; D051381:Rats; D011919:Rats, Inbred Strains; D064030:S100 Calcium Binding Protein G; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D064026:Calbindins; D006892:Hydroxydopamines; D064030:S100 Calcium Binding Protein G; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine